Oligosaccharidoses

Leroy, Jules

doi:10.1016/b978-0-12-383834-6.00108-7

Emery and Rimoin's Principles and Practice of Medical Genetics 2013

DOI: 10.1016/b978-0-12-383834-6.00108-7

|View full text |Cite

Oligosaccharidoses

Jules Leroy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 278 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation

Lin,

Li,

Chen

et al. 2024

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveExpand genetic screening for atypical Type I sialidosis (ST‐1) could address its underdiagnosed in both progressive myoclonic ataxia (PMA) and ataxia patients. To evaluate the potential founder effect of mutation in the population.MethodsWe enrolled 231 patients with PMA or ataxia from the First Affiliated Hospital of Fujian Medical University. Through Whole Exome Sequencing and Sanger sequencing, we identified the causative gene in patients. Haplotype analysis was employed to explore a potential founder effect of the NEU1 c.544A>G mutation.ResultsA total of 31 patients from 23 unrelated families were genetically diagnosed with ST‐1. A significant 80.6% of these patients were homozygous for the c.544A>G mutation. We discovered six different NEU1 variants, including two novel mutations: c.951_968del and c.517T>G. The mean age of onset was 18.0 ± 7.1 years. The clinical spectrum of ST‐1 featured ataxia and myoclonus as the most common initial symptoms. Over 40% suffered from controlled generalized tonic–clonic seizures. Mobility and independence varied greatly across the cohort. Cherry‐red spots were rare, occurring in just 9.5% (2/21) of patients. Brain MRIs were typically unremarkable, except for two patients with unusual findings. EEGs showed diffuse paroxysmal activity in 17 patients. The c.544A>G mutation in NEU1 is a founder variant in Fujian, with a unique haplotype prevalent in East Asians.InterpretationST‐1 should be suspected in patients with PMA or ataxia in Southeast China, even without macular cherry‐red spots and seizures, and the premier test could be a variant screening of the founder variant NEU1 c.544A>G.

show abstract

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation

Lin,

Li,

Chen

et al. 2024

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Oligosaccharidoses

Cited by 1 publication

References 278 publications

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation

Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation

Contact Info

Product

Resources

About